IP News
The CRISPR Patent War: ToolGen’s Strategic Advantage and the UPC’s New Global Frontier
•
6 min read
•194 views
//
The long-standing battle over CRISPR-Cas9 gene-editing technology has shifted focus to Europe. As ToolGen consolidates its position at the European Patent Office (EPO), the emergence of the Unified Patent Court (UPC) and its ability to grant multi-national injunctions is creating a high-stakes environment for global biotech companies. This development signals a potential shift in the licensing landscape, where ToolGen—once considered an underdog—is now a formidable senior party.
Recent developments in the CRISPR-Cas9 patent landscape highlight two converging trends: the validation of ToolGen’s foundational patents by the EPO and the increasing utilization of the European Unified Patent Court (UPC). ToolGen recently received notification of patent registration from the EPO for its technology regarding the introduction of CRISPR-Cas9 Ribonucleoprotein (RNP) complexes into mammalian cells. Simultaneously, legal experts are closely monitoring the UPC's potential to issue cross-border injunctions, which could effectively block the commercialization of CRISPR-based therapies across multiple European nations with a single court order.
The CRISPR patent war has historically been a three-way conflict between the CVC Group (University of California, University of Vienna, and Emmanuelle Charpentier), the Broad Institute (MIT and Harvard), and ToolGen. While the CVC and Broad groups were awarded the Nobel Prize and early US patents respectively, ToolGen has maintained a strategic edge through its focus on eukaryotic applications (plants, animals, and humans).
Senior Party Status: In the US Patent and Trademark Office (USPTO) interference proceedings, ToolGen was designated as the 'Senior Party' in certain cases against both CVC and Broad. This means the burden of proof lies with the competitors to show they invented the technology before ToolGen’s filing date.
The European Shift: Unlike the US 'First-to-Invent' system (pre-2013), Europe operates on a 'First-to-File' basis. ToolGen’s early filing date and successful defense at the EPO position it as a primary gatekeeper for CRISPR technology in the EU.
For patent attorneys and IP strategists, the interplay between EPO registrations and UPC enforcement is a masterclass in global patent strategy.
The most significant risk—and opportunity—is the UPC's jurisdiction. Under the Unitary Patent system, a single infringement lawsuit can lead to an injunction covering 17+ EU member states. This grants ToolGen immense leverage in licensing negotiations. Companies developing CRISPR therapies must now conduct thorough Freedom to Operate (FTO) analyses that specifically account for ToolGen’s European portfolio.
The CRISPR landscape is famously a 'patent thicket.' Most commercial players have sought licenses from Broad or CVC. However, if ToolGen’s patents are upheld as foundational for eukaryotic use, existing licenses may not be sufficient. Legal operations teams must prepare for 'stacking' royalties or renegotiating multi-party licensing deals to avoid litigation.
The CRISPR saga is far from over, but the center of gravity has moved. We should watch for the first major UPC infringement case involving CRISPR technology. A single ruling could redefine the market value of gene-editing firms overnight. For IP professionals, the priority is clear: monitor the UPC’s evolving jurisprudence on preliminary injunctions and re-evaluate the priority chains of foundational biotech patents. ToolGen’s rise serves as a reminder that being a 'dark horse' in the early stages of a tech race can lead to a dominant position in the commercial endgame.